| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | 5T4; 5T4AG; M6P1; TPBG; 5T4 oncofetal antigen; Trophoblast glycoprotein |
| Entrez GeneID | 7162 |
| WB Predicted band size | Calculated MW: 46 kDa; Observed MW: 78 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthetic peptide of human 5T4 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是关于5T4抗体的模拟参考文献示例(仅供参考，非真实文献)：
---
1. **文献名称**：*Targeting 5T4 with a novel antibody-drug conjugate for solid tumor therapy*
**作者**：Smith A, et al.
**摘要**：研究开发了一种新型5T4抗体-药物偶联物(ADC)，通过体外和小鼠模型实验证明其对5T4高表达的结直肠癌和卵巢癌细胞具有选择性杀伤作用，并显著抑制肿瘤生长。
2. **文献名称**：*5T4-specific bispecific antibody enhances T-cell cytotoxicity in metastatic breast cancer*
**作者**：Jones R, et al.
**摘要**：报道了一种靶向5T4和CD3的双特异性抗体，可激活T细胞并诱导其对5T4阳性乳腺癌细胞的杀伤，临床前数据显示其显著减少肺转移灶。
3. **文献名称**：*Structural optimization of 5T4 monoclonal antibody improves antitumor efficacy*
**作者**：Lee C, et al.
**摘要**：通过抗体工程技术优化5T4单抗的亲和力和稳定性，在肺癌异种移植模型中显示出更强的肿瘤抑制效果和延长的小鼠生存期。
4. **文献名称**：*5T4 as a therapeutic target in cancer: Mechanisms and clinical prospects*
**作者**：Brown K, et al.
**摘要**：综述了5T4在肿瘤发生、转移和免疫逃逸中的作用，总结了当前基于5T4抗体的治疗策略(如ADC、CAR-T)的临床进展与挑战。
---
**注意**：以上文献为模拟内容，实际研究中请通过学术数据库(如PubMed、Web of Science)检索真实文献。
The 5T4 antibody targets the 5T4 oncofetal antigen, also known as trophoblast glycoprotein (TPBG), a cell-surface glycoprotein overexpressed in various carcinomas (e.g., colorectal, ovarian, gastric) but minimally expressed in healthy tissues. First identified in trophoblast cells during embryogenesis, 5T4 plays roles in cell adhesion, motility, and epithelial-mesenchymal transition (EMT), promoting cancer metastasis and invasiveness. Its tumor-restricted expression makes it an attractive therapeutic target.
5T4-specific antibodies have been explored in cancer immunotherapy, including antibody-drug conjugates (ADCs), CAR-T cells, and cancer vaccines. For instance, the MVA-5T4 (TroVax) vaccine showed promise in early-phase trials by eliciting immune responses, though late-stage trials yielded limited clinical benefits. ADCs like A1mcMMAF, combining anti-5T4 antibodies with cytotoxic agents, demonstrated preclinical efficacy in tumor models. Challenges include tumor heterogeneity, variable 5T4 expression, and immune evasion mechanisms.
Recent efforts focus on optimizing antibody design (e.g., bispecific formats) and combination therapies to enhance targeting and overcome resistance. Despite mixed clinical outcomes, 5T4 remains a viable candidate for precision oncology, with ongoing research refining its therapeutic potential.
×
